Illumina (NASDAQ:ILMN – Get Rating) and SeqLL (NASDAQ:SQL – Get Rating) are both medical companies, but which company is better? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Benefits and evaluation
This table compares the gross revenue, earnings per share and valuation of Illumina and SeqLL.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|Illuminated||$4.53 billion||11.68||$762.00 million||$5.05||66.63|
|SeqLL||$210,000.00||69.64||-$3.70 million||N / A||N / A|
Illumina has higher revenue and profit than SeqLL.
Institutional and Insider Ownership
85.4% of Illumina shares are held by institutional investors. By comparison, 0.7% of SeqLL’s shares are held by institutional investors. 0.2% of Illumina stock is held by company insiders. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock will outperform the market over the long term.
This table compares the net margins, return on equity, and return on assets of Illumina and SeqLL.
|Net margins||Return on equity||return on assets|
|SeqLL||N / A||N / A||N / A|
This is a breakdown of recent recommendations for Illumina and SeqLL, as reported by MarketBeat.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
Illumina currently has a consensus target price of $409.67, indicating a potential upside of 21.75%. SeqLL has a consensus target price of $3.00, indicating a potential upside of 143.90%. Given SeqLL’s stronger consensus rating and higher likely upside, analysts clearly believe SeqLL is more favorable than Illumina.
Illumina beats SeqLL on 8 out of 11 factors compared between the two stocks.
About Illumina (Get an evaluation)
Illumina, Inc. provides sequencing solutions and chips for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomics solutions in research and clinical settings for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts and development and licensing agreements, as well as cancer detection testing services. Its customers include genomics research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostics and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America and the Asia-Pacific region, as well as through life science distributors in various markets in Europe, the Asia-Pacific region, Latin America, the Middle East and Africa. The company was incorporated in 1998 and is based in San Diego, California.
About SeqLL (Get an evaluation)
SeqLL Inc. is a worldwide life science research and instrumentation services company. The company designs, develops and manufactures genetic analysis technologies. It offers a true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has entered into a collaboration agreement with Bernstein Lab, Ting Lab, Jackson Lab for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical companies and biotechnology companies and not-for-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.
Get news and reviews for Illumina Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Illumina and related companies with MarketBeat.com’s free daily email newsletter.